- Home
- CSTL vs DIAX Comparison
CSTL vs DIAX Comparison
Compare CSTL & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- DIAX
- Stock Information
- Founded
- CSTL 2007
- DIAX 2005
- Country
- CSTL United States
- DIAX United States
- Employees
- CSTL N/A
- DIAX N/A
- Industry
- CSTL Medical Specialities
- DIAX Finance Companies
- Sector
- CSTL Health Care
- DIAX Finance
- Exchange
- CSTL Nasdaq
- DIAX Nasdaq
- Market Cap
- CSTL 576.3M
- DIAX 539.0M
- IPO Year
- CSTL 2019
- DIAX N/A
- Fundamental
- Price
- CSTL $19.78
- DIAX $14.49
- Analyst Decision
- CSTL Strong Buy
- DIAX
- Analyst Count
- CSTL 6
- DIAX 0
- Target Price
- CSTL $40.00
- DIAX N/A
- AVG Volume (30 Days)
- CSTL 403.1K
- DIAX 96.6K
- Earning Date
- CSTL 05-01-2025
- DIAX 01-01-0001
- Dividend Yield
- CSTL N/A
- DIAX 7.93%
- EPS Growth
- CSTL N/A
- DIAX N/A
- EPS
- CSTL 0.62
- DIAX N/A
- Revenue
- CSTL $332,069,000.00
- DIAX N/A
- Revenue This Year
- CSTL N/A
- DIAX N/A
- Revenue Next Year
- CSTL $6.01
- DIAX N/A
- P/E Ratio
- CSTL $32.29
- DIAX N/A
- Revenue Growth
- CSTL 51.09
- DIAX N/A
- 52 Week Low
- CSTL $16.97
- DIAX $12.80
- 52 Week High
- CSTL $35.84
- DIAX $15.12
- Technical
- Relative Strength Index (RSI)
- CSTL 36.62
- DIAX 43.04
- Support Level
- CSTL $19.22
- DIAX $14.15
- Resistance Level
- CSTL $20.30
- DIAX $14.68
- Average True Range (ATR)
- CSTL 0.81
- DIAX 0.18
- MACD
- CSTL 0.23
- DIAX 0.04
- Stochastic Oscillator
- CSTL 43.33
- DIAX 69.53
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, among others. The company's test portfolio consists of test offerings to aid clinicians in the diagnosis and treatment of cancers or precancerous diagnoses in the fields of dermatology, gastroenterology, and ophthalmology and a pharmacogenomics ("PGx") test to guide optimal drug treatment for patients diagnosed with depression, anxiety, and other mental health conditions.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.